UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY. (12th June 2019)

• Record Type: Journal Article
• Authors: Zinzani, P.; Samaniego, F.; Jurczak, W.; Lech‐Maranda, E.; Ghosh, N.; Anz, B.; Patten, P.; Reeves, J.; Leslie, L.A.; Smolewski, P.; Chavez, J.C.; Scarfo, L.; Derenzini, E.; Burke, J.M.; Sharman, J.; Kolibaba, K.; O'Connor, O.A.; Cheah, C.Y.; Miskin, H.P.; Sportelli, P.; Weiss, M.S.; Fowler, N.H.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 182
• Page End: 183
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.139_2629
• Languages: English
• ISSNs: 0278-0232